SEP-226330

SEP-226330 is a small molecule triple reuptake inhibitor (SNDRI) that was developed by Sepracor (now Sunovion Pharmaceuticals) for the treatment of restless legs syndrome (RLS). It acts by inhibiting the reuptake of three key monoamine neurotransmitters: serotonin, norepinephrine, and dopamine. By increasing the synaptic concentrations of these neurotransmitters, SEP-226330 was intended to modulate the neural pathways associated with the sensorimotor symptoms of RLS. The compound was evaluated in a Phase 2 randomized, double-blind, placebo-controlled pilot study in Iceland, conducted in collaboration with deCODE genetics. This trial (NCT00683111) utilized the International Restless Legs Syndrome Study Group (IRLSSG) rating scale as the primary efficacy endpoint. Following the completion of early-phase clinical evaluation, development of the compound was discontinued, and it is no longer listed in the active pipeline of Sunovion Pharmaceuticals.